House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Infectious diseases

Histoplasmosis in adults, children and pregnancy

IDSA · 2026 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

The IDSA histoplasmosis update combines the earlier recommendations for asymptomatic pulmonary nodules and mild or moderate acute pulmonary disease with a later consensus statement on initial treatment of severe pulmonary or disseminated disease. Treatment depends on syndrome, immune status, progression and toxicity risk. This summary preserves the distinction between very-low-certainty conditional recommendations and expert consensus, including formulation-specific itraconazole guidance.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Asymptomatic pulmonary nodules

  • For adults or children with asymptomatic non-calcified histoplasmosis nodules, no other active sites, or asymptomatic untreated prior infection, IDSA conditionally suggests against routine antifungal treatment solely to prevent reactivation. The certainty of evidence is very low. [1]
  • For an asymptomatic histoplasmoma without another active site, or asymptomatic untreated prior infection, monitor clinical and imaging changes closely or consider treatment when the patient has elevated dissemination or severe-disease risk, particularly moderate or high-risk immunocompromise. Do not treat solely calcified pulmonary nodules. [1]

Mild and moderate acute pulmonary disease

  • In immunocompetent adults and children with mild acute pulmonary histoplasmosis, the panel conditionally suggests against routine treatment. Consider treatment when illness is prolonged, pulmonary infiltrates progress or hilar or mediastinal nodes enlarge. [1]
  • For immunocompetent patients with moderate acute pulmonary disease, either treatment or observation is a conditional option. Worsening or prolonged symptoms, progressive infiltrates, enlarging nodes and greater severity favour treatment; consider interactions, harms, benefits and financial burden. [1]
  • For immunocompromised adults and children with mild or moderate acute pulmonary disease and moderate-to-high dissemination risk, the panel conditionally suggests treatment. Asymptomatic or mild disease with a lesser degree of immunocompromise may not require it. [1]

Itraconazole for treated nonsevere pulmonary disease

  • When treatment of mild or moderate pulmonary disease is indicated, itraconazole is preferred. For adults, original capsules or solution are given as 200 mg three times daily for 3 days, then 200 mg twice daily for 6–12 weeks. [1]
  • When treating mild or moderate acute pulmonary histoplasmosis in children receiving original itraconazole capsules or solution, the stated dose is 5 mg/kg per dose, at most 200 mg, three times daily for 3 days, then 5 mg/kg per dose twice daily, no more than 400 mg daily, for 6–12 weeks. [1]
  • For adult SUBA itraconazole, the mild/moderate regimen is 130 mg three times daily for 3 days followed by 130 mg twice daily for 6–12 weeks. Paediatric use is off-label and requires pharmacist input for children able to swallow capsules. [1]
  • Perform therapeutic drug monitoring for itraconazole. The mild/moderate guidance associates an itraconazole-component trough above 1 mg/L and below 3–4 mg/L with efficacy and lower toxicity; non-trough levels can also be used because of the long half-life. [1]

Initial treatment of severe histoplasmosis

  • The severe-disease update is an expert-consensus statement: start amphotericin B for severe acute pulmonary or disseminated histoplasmosis, with liposomal amphotericin B preferred over other formulations. [1]
  • The stated liposomal amphotericin B dose is 3 mg/kg intravenously once daily for severe non-CNS disease and 5 mg/kg intravenously once daily for CNS histoplasmosis. [1]
  • The optimal induction duration is uncertain. Non-CNS treatment has historically used 7–14 days, but earlier oral transition may fit a clinically improving patient tolerating oral medicines or one developing liposomal amphotericin toxicity; consider the harms of longer courses. [1]
  • For CNS histoplasmosis, induction for 4–6 weeks is generally suggested, guided by CNS symptom resolution and improved cerebrospinal-fluid findings. This is distinct from the shorter historical non-CNS induction approach. [1]

Post-induction treatment and monitoring

  • After initial clinical improvement in severe disease, itraconazole is the preferred oral step-down azole. Some experts start its loading and maintenance doses before stopping amphotericin to establish target concentrations; evidence does not support choosing another azole for initial therapy. [1]
  • For severe histoplasmosis, check itraconazole concentrations after 1–2 weeks. The consensus suggests a random itraconazole-component concentration of 1–4 mg/L by chromatographic assay to balance exposure and toxicity. [1]

Pregnancy and individualised decisions

  • In pregnancy, weigh benefits and harms with infectious-disease and maternal-fetal-medicine expertise when possible. If treatment is needed, avoid azoles during the first trimester when possible and use liposomal amphotericin B instead. [1]

Limitations and use

  • The current page combines March 2025 recommendations with the September 2026 severe-disease consensus; not every statement was newly issued in 2026.
  • Detailed immune-risk classification and full chronic, CNS-maintenance or disseminated-disease duration protocols are outside this focused summary.
  • Formulations and populations have distinct itraconazole regimens. The mild/moderate duration must not be carried over to severe disseminated disease.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Histoplasmosis in adults, children and pregnancy

    Selected recommendation material consulted

Original guideline

Publication details

Issuing organisation
IDSA
Publisher’s latest update
16 September 2026
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Asymptomatic pulmonary nodules
  • Mild and moderate acute pulmonary disease
  • Itraconazole for treated nonsevere pulmonary disease
  • Initial treatment of severe histoplasmosis
  • Post-induction treatment and monitoring
  • Pregnancy and individualised decisions
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House